Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The funds will be used to develop the next generation of small molecule drugs and to advance and expand PharmEnable’s portfolio of wholly owned and co-discovery projects across oncology and neurology targets, as well as supporting further platform R&D.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 22, 2023
Details : The strategic collaboration will aim to accelerate drug discovery in neurodegenerative disease, tackling undisclosed targets in a multi-year programme. Denali will be responsible for the further lead optimisation, development, and commercialisation of th...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2022